Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC-Reference-Cited by-同舟云学术

Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC

Published:2021-08 Issue: Volume:158 Page:126-136
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Zhang Shannon S.,Nagasaka Misako^ORCID,Zhu Viola W.,Ou Sai-Hong Ignatius^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference69 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer;Rikova;Cell,2007

3. Is retention of the 5’ non-oncogenic ALK fusion variant a novel poor prognostic factor in ALK-positive NSCLC?;Hsiao;J. Thorac. Oncol.,2020

4. Catalog of 5’ fusion partners in ALK-positive NSCLC circa;Ou;JTO Clin. Res. Rep.,2020

5. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology;Ou;Oncologist,2012

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report;Case Reports in Oncology;2024-08-27

2. EML4-ALK variant-specific genetic interactions shape lung tumorigenesis;2024-08-27

3. SIRT1 silencing promotes EMT and Crizotinib resistance by regulating autophagy through AMPK/mTOR/S6K signaling pathway in EML4‐ALK L1196M and EML4‐ALK G1202R mutant non‐small cell lung cancer cells;Molecular Carcinogenesis;2024-07-30

4. Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives;Frontiers in Oncology;2024-07-11

5. Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database;Journal of Thoracic Oncology;2024-07